Repository logo
Communities & Collections
All of MSAR
  • English
  • العربية
  • বাংলা
  • Català
  • Čeština
  • Deutsch
  • Ελληνικά
  • Español
  • Suomi
  • Français
  • Gàidhlig
  • हिंदी
  • Magyar
  • Italiano
  • Қазақ
  • Latviešu
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Српски
  • Svenska
  • Türkçe
  • Yкраї́нська
  • Tiếng Việt
Log In
New user? Click here to register. Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Amany A. Tohamy"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Item
    Cinnamic acid Attenuates Cisplatin-Induced Hepatotoxicity and Nephrotoxicity
    (National Academy of science, 2016-01-06) Amany A. Tohamy; Ahmed M. Aref; Ahmed E. Abdel Moneim; Romissaa H. Sayed
    We investigated the effects of cinnamic acid (CA, 20 mg/kg body weight) on cisplatin (CP)-induced hepto and nephrotoxicity in mice. CP (5 mg/kg bwt) was injected intraperitoneally and CA was given by gastric gavage for 5 days pre- and post-CP injection. After 5 days of CP injection, CP-induced injuries of the hepatic and renal tissues which were evidenced (i) histopathological damage of the hepatic and renal tissues, (ii) as increases in liver and kidney function parameters, (iii) as increases in lipid peroxidation and nitric oxide, and (iv) as decrease in glutathione content. In contrast, the oral administration of CA concurrently to CP intoxicated mice brought back lipid peroxidation, nitric oxide, glutathione levels to near normalcy. Moreover, the histological observations evidenced that CA effectively rescues the liver and kidney from CP mediated oxidative damage. Therefore, cinnamic acid can be considered a potential candidate for protection of hepato-and nephrotoxicity induced by cisplatin.

October University for Modern Sciences and Arts Established by Dr. Nawal El Degwi in 1996 copyright © 2019-2024

DSpace software copyright © 2002-2025 LYRASIS

  • Privacy policy
  • End User Agreement
  • Send Feedback